The bar low­ers yet again for PRV prices, with Ky­owa/Ul­tragenyx sell­ing at $80.6M

Are we back where we start­ed with the price tag of pri­or­i­ty re­view vouch­ers? Their dwin­dling val­ue slid fur­ther south this morn­ing, with news that Ky­owa Hakko Kirin and its part­ner Ul­tragenyx sold off their rare dis­ease PRV for $80.6 mil­lion. That’s a far cry from the go-go days of Ab­b­Vie’s his­toric $350 mil­lion PRV pur­chase in 2015.

Ky­owa re­vealed Wednes­day morn­ing that the duo sold its PRV for a rare pe­di­atric dis­ease drug to an undis­closed buy­er dur­ing Q2, ac­cord­ing to a Bio­Cen­tu­ry re­port. The com­pa­nies re­ceived the vouch­er in April when the FDA ap­proved Crysvi­ta to treat ab­nor­mal­ly low lev­els of phos­phate in the blood.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER